LifeStance Health Group (LFST) Projected to Post Quarterly Earnings on Thursday

LifeStance Health Group (NASDAQ:LFST) is anticipated to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect LifeStance Health Group to post earnings of ($0.01) per share and revenue of $355.0620 million for the quarter. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The company had revenue of $345.31 million for the quarter, compared to the consensus estimate of $345.05 million. During the same period in the previous year, the firm earned ($0.06) earnings per share. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts expect LifeStance Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeStance Health Group Stock Up 1.2%

Shares of NASDAQ LFST opened at $4.98 on Wednesday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.19. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.61. The firm’s fifty day moving average is $5.29 and its 200 day moving average is $5.27. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -99.60 and a beta of 1.16.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, major shareholder Silversmith Partners I. Gp, Llc sold 3,592,357 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $18,213,249.99. Following the transaction, the insider owned 14,324,197 shares of the company’s stock, valued at approximately $72,623,678.79. This represents a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Summit Partners L. P sold 8,407,643 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.07, for a total value of $42,626,750.01. Following the completion of the transaction, the insider directly owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. This represents a 20.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 20,407,643 shares of company stock valued at $103,466,750. 6.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc lifted its holdings in LifeStance Health Group by 2.4% in the second quarter. Legal & General Group Plc now owns 144,263 shares of the company’s stock valued at $746,000 after acquiring an additional 3,331 shares during the period. Oxford Asset Management LLP raised its stake in shares of LifeStance Health Group by 5.1% in the second quarter. Oxford Asset Management LLP now owns 92,750 shares of the company’s stock worth $480,000 after buying an additional 4,495 shares during the period. Royal Bank of Canada raised its stake in shares of LifeStance Health Group by 63.4% in the first quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock worth $468,000 after buying an additional 27,244 shares during the period. Ameriprise Financial Inc. raised its stake in shares of LifeStance Health Group by 302.0% in the second quarter. Ameriprise Financial Inc. now owns 78,164 shares of the company’s stock worth $404,000 after buying an additional 58,721 shares during the period. Finally, AQR Capital Management LLC raised its stake in shares of LifeStance Health Group by 223.0% in the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after buying an additional 35,554 shares during the period. Institutional investors own 85.50% of the company’s stock.

Analyst Upgrades and Downgrades

LFST has been the topic of several analyst reports. Wall Street Zen downgraded shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Zacks Research raised shares of LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 7th. UBS Group lifted their target price on shares of LifeStance Health Group from $8.50 to $9.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. BTIG Research initiated coverage on LifeStance Health Group in a report on Friday, July 25th. They set a “buy” rating and a $8.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of LifeStance Health Group in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $8.50.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.